- Phase 3 CATT1 trial enrollment completed with 166 patients; topline results expected mid-2027
- Q3 operating loss widened to $12.4M vs $10.7M YoY with zero revenue
- Cash and cash equivalents stood at $77.2M as of Sept 30, 2026, down from $88.9M at year-end 2025
Why is $VTVT moving today? · SEC 8-K archive
$VTVT SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $VTVT: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $VTVT filing catalyst
Why did $VTVT trigger an AI stock catalyst alert?
$VTVT triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.0/10). Headline: vTv Therapeutics Reports Q3 Results; Phase 3 CATT1 Enrollment Complete, Topline Mid-2027. Key points: - Phase 3 CATT1 trial enrollment completed with 166 patients; topline results expected mid-2027 - Q3 operating loss widened to $12.4M vs $10.7M YoY with zero revenue - Cash and cash equivalents stood at $77.2M as of Sept 30, 2026, down from $88.9M at year-end 2025
How did $VTVT stock react after the SEC filing?
After the SEC 8-K for $VTVT, observed market reaction: T0 price $21.74. Past moves do not guarantee future results.
Where can I get real-time $VTVT SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $VTVT via Telegram and the VIP Web Terminal from €10/month.